Phreesia, Inc. (NYSE:PHR) Receives Consensus Rating of “Buy” from Brokerages

Phreesia, Inc. (NYSE:PHR) has received an average rating of “Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. Twelve investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $31.00.

Several brokerages recently weighed in on PHR. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Robert W. Baird decreased their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Finally, KeyCorp increased their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th.

Insider Transactions at Phreesia

In other Phreesia news, Director Michael Weintraub sold 15,152 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $21.01, for a total transaction of $318,343.52. Following the transaction, the director now directly owns 242,827 shares in the company, valued at $5,101,795.27. This represents a 5.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Evan Roberts sold 2,873 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $76,450.53. Following the transaction, the chief operating officer now directly owns 779,993 shares of the company’s stock, valued at approximately $20,755,613.73. This represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,034 shares of company stock valued at $2,378,581. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of the company. Trust Point Inc. increased its holdings in shares of Phreesia by 3.5% in the 3rd quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after acquiring an additional 607 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in Phreesia by 3.2% during the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares during the last quarter. Rhumbline Advisers boosted its holdings in Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after purchasing an additional 853 shares during the period. The Manufacturers Life Insurance Company increased its stake in Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the last quarter. Finally, MetLife Investment Management LLC raised its holdings in shares of Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after purchasing an additional 1,120 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Trading Up 1.6 %

NYSE PHR opened at $27.24 on Thursday. The company has a market cap of $1.58 billion, a P/E ratio of -18.53 and a beta of 0.94. Phreesia has a 12 month low of $17.07 and a 12 month high of $29.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company has a 50-day moving average of $23.54 and a 200-day moving average of $22.84.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.58) earnings per share. As a group, equities analysts predict that Phreesia will post -1.1 earnings per share for the current year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.